InvestorsHub Logo
Followers 215
Posts 22621
Boards Moderated 0
Alias Born 10/22/2006

Re: None

Friday, 02/16/2018 7:03:07 AM

Friday, February 16, 2018 7:03:07 AM

Post# of 30368
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)
GlobeNewswire
7:00 AM ET
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter ("CRL") for the New Drug Application ("NDA") of Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SEEL News